EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-Treatment Immune Signatures and Cytokine Patterns Associated with Vedolizumab Response in Inflammatory Bowel Disease: A Pilot Study

Laurien A. Waaijer, Xuehui He, Bram van Cranenbroek, Judith L. Logmans, Manon Kolkman, Annemijn J. Arns, Esther van Rijssen, Pepijn W. A. Thomas, Monica E. W. Derks, Frank Hoentjen, Marien I. de Jonge, Marjolijn Duijvestein und 1 weitere

Cells · 12.11.2026 · 15 (22) · 2061

DOI: 10.3390/cells15222061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 12.11.2026. Verfasst von Laurien A. Waaijer und 12 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International AG.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vedolizumab, a gut-selective integrin antagonist, is an effective therapy for inflammatory bowel disease (IBD), but immune correlates of treatment response remain poorly understood. We performed longitudinal immune profiling of blood and serum from 20 vedolizumab-treated IBD patients (15 Crohn’s disease, 5 ulcerative colitis) to characterize treatment-associated immune changes and identify baseline features associated with clinical response. Samples were collected at baseline and week 14. Immune cell phenotyping was performed using five 10-color flow cytometry panels, while serum proteomics was assessed with the Olink® 96 Inflammation panel. Age- and sex-matched healthy controls (HCs) were included for comparison. IBD patients could be distinguished from HCs based primarily on immune cell profiles, whereas serum proteomic differences were less pronounced. Vedolizumab treatment induced modest changes in immune cell composition and serum proteins. Clinical responders exhibited shifts in three immune populations and a reduction in CXCL8 and IL-6 levels by week 14. Unsupervised hierarchical clustering of five baseline immune cell populations stratified patients into two groups that broadly corresponded with treatment outcome. Furthermore, non-responders exhibited increased IFNγ and CXCL9 levels. However, these immune cell populations and proteins did not remain significant upon correcting for multiple testing. Taken together, we identified exploratory immune and cytokine patterns associated with vedolizumab response that may support the development of precision medicine approaches in IBD.

Förderung

  • Takeda Pharmaceuticals International AG

Zitieren

APA

Waaijer, L. A., He, X., Cranenbroek, B. V., Logmans, J. L., Kolkman, M., Arns, A. J., Rijssen, E. V., Thomas, P. W. A., Derks, M. E. W., Hoentjen, F., Jonge, M. I. D., Duijvestein, M., & Koenen, H. J. P. M. (2026). Pre-Treatment Immune Signatures and Cytokine Patterns Associated with Vedolizumab Response in Inflammatory Bowel Disease: A Pilot Study. Cells, 15(22), 2061. https://doi.org/10.3390/cells15222061

Vancouver

Waaijer LA, He X, Cranenbroek BV, Logmans JL, Kolkman M, Arns AJ, et al. Pre-Treatment Immune Signatures and Cytokine Patterns Associated with Vedolizumab Response in Inflammatory Bowel Disease: A Pilot Study. Cells. 2026;15(22):2061. doi:10.3390/cells15222061

BibTeX
@article{Waaijer2026,
  author = {Waaijer, Laurien A. and He, Xuehui and Cranenbroek, Bram van and Logmans, Judith L. and Kolkman, Manon and Arns, Annemijn J. and Rijssen, Esther van and Thomas, Pepijn W. A. and Derks, Monica E. W. and Hoentjen, Frank and Jonge, Marien I. de and Duijvestein, Marjolijn and Koenen, Hans J. P. M.},
  title = {Pre-Treatment Immune Signatures and Cytokine Patterns Associated with Vedolizumab Response in Inflammatory Bowel Disease: A Pilot Study},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {2061},
  doi = {10.3390/cells15222061}
}
Kostenlos starten →